Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 5.27%
As of Wednesday, June 03, Radiopharm Theranostics Limited’s RADX share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Radiopharm Theranostics Limited (RADX)
Radiopharm Theranostics Limited RADX
$2.05
-0.11
-5.09%
September 3, 2026 9:30:08 AM
EST
Volume: 1,463
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Commentary & Analysis
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 6.95%
As of Tuesday, May 19, Radiopharm Theranostics Limited’s RADX share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Down 5.30%
As of Friday, March 20, Radiopharm Theranostics Limited’s RADX share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Up 7.07%
As of Friday, March 06, Radiopharm Theranostics Limited’s RADX share price has surged by 7.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Radiopharm Theranostics Limited’s (RADX) Stock Is Up 6.47%
As of Friday, January 09, Radiopharm Theranostics Limited’s RADX share price has surged by 6.47%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | RADX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $28.0 | $288.9 | 12% |
|
| Shares Out (Mil) | 1,713.0 | 54.0 | 97% |
|
| Institutional Ownership | 65.4% | 93.1% | 41% |
|
| Float (Mil) | 3,601.5 | 41.4 | 97% |
|
| Beta | 0.75 | 0.94 | 44% |
|
| Avg Daily Volume (000s) | 78 | 480 | 33% |
|
| Price Change (52-week) |
(61.4%) | 59.9% | 11% |
|
| Growth | RADX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RADX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11 | $37 | 9% |
|
| Net Income (TTM) (Mil) | ($31) | ($43) | 20% |
|
| EPS (TTM) | ($0.013) | ($1.500) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($25) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $35 | $190 | 14% |
|
| Valuation | RADX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 216.00 | 2.84 | 100% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | RADX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 81.5% | 66.9% | 89% |
|
| Net Margin | (408.4%) | (74.2%) | 2% |
|
| ROA | (52.7%) | (47.7%) | 11% |
|
| ROE | (92.1%) | (55.0%) | 10% |
|
| Liabilities to Assets | 45.2% | 29.6% | 36% |
|
| F-Score | 4 | 3 | 33% |
|
Radiopharm Theranostics Limited did not pass any screens on 9/2/2026.
